Preclinical evaluation of [18F]JNJ42259152 as a PET tracer for PDE10A

NeuroImage

Volumn 82, Issue , 2013, Pages 13-22

  Celen, S ^a   Koole, M ^a   Ooms, M ^a   De Angelis, M ^b   Sannen, I ^a   Cornelis, J ^a   Alcazar, J ^b   Schmidt, M ^b   Verbruggen, A ^a   Langlois, X ^b   Van Laere, K ^a   Andres J I ^b   Bormans, G ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Brain imaging; Fluorine 18; Kinetic modeling; PDE10A; PET

Indexed keywords

FLUORINE 18; JNJ 41510417 F 18; JNJ 42259152 F 18; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DEFLUORINATION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIPOPHILICITY; MALE; MOUSE; NEUROIMAGING; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RECEPTOR OCCUPANCY;

BRAIN IMAGING; FLUORINE-18; KINETIC MODELING; PDE10A; PET;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORINE RADIOISOTOPES; MACACA; METABOLIC CLEARANCE RATE; MICE; MICE, KNOCKOUT; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; PYRIDINES; RADIOISOTOPES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84879705287     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.04.123     Document Type: Article

References (30)

1. Ametamey S.M., Honer M., Schubiger P.A. Molecular imaging with PET. Chem. Rev. 2008, 108:1501-1516.
2. Andrés J.-I., De Angelis M., Alcazar J., Iturrino L., Langlois X., Dedeurwaerdere S., Lenaerts I., Vanhoof G., Celen S., Bormans G. Synthesis, in vivo occupancy and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J. Med. Chem. 2011, 54:5820-5835.
3. 18F]MNI659. J. Nucl. Med. 2012, 53(Supplement 1):361.
4. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58:488-520.
5. 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J. Nucl. Med. 2010, 51:1584-1591.
6. Chappie T.A., Helal C.J., Hou X. Current landscape of phosphodiesterase 10A (PDE10A) inhibition. J. Med. Chem. 2012, 55:7299-7331.
7. Conti M., Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 2007, 76:481-511.
8. Giampà C., Patassini S., Borreca A., Laurenti D., Marullo F., Bernardi G., Menniti F.S., Fusco F.R. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol. Dis. 2009, 34:450-456.
9. Giampà C., Laurenti D., Anzilotti S., Bernardi G., Menniti F.S., Fusco F.R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 2010, 5(10):1-14.
10. Giorgi M., Melchiorri G., Nuccetelli V., D'Angelo V., Martorana A., Sorge R., Castelli V., Bernardi G., Sancesario G. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology. Neurobiol. Dis. 2011, 43:293-303.
11. Grauer S.M., Pulito V.L., Navarra R.L., Kelly M.P., Kelley C., Graf R., Langen B., Logue S., Brennan J., Jiang L., Charych E., Egerland U., Liu F., Marquis K.L., Malamas M., Hage T., Comery T.A., Brandon N.J. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J. Pharmacol. Exp. Ther. 2009, 331:574-590.
12. Kharasch E.D., Thummel K.E. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993, 79:795-807.
13. 18F-JNJ42259152: a novel radioligand for human in vivo PDE10A brain imaging. J. Nucl. Med. 2012, 53(Supplement 1):1629.
14. Lakics V., Karran E.H., Boess F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59:367-374.
15. Mennitti F.S., Faraci W.S., Schmid C.J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 2006, 5:660-669.
16. 11C]-MP10 and its regio-isomer as potential radioligands for positron emission tomography imaging of phosphodieasterase-10A in the brain. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:S206.
17. 18F]-isoJNJ41510417 as potential radioligands for positron emission tomography imaging of phosphodiesterase-10A in the brain. J. Label. Compd. Radiopharm. 2011, 54:S294.
18. Passchier J., Gee A., Willemsen A., Vaalburg W., van Waarde A. Measuring drug-related receptor occupancy with positron emission tomography. Methods 2002, 27:278-286.
19. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol. Sci. 2009, 30:431-440.
20. 11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucl. Med. Biol. 2011, 38:875-884.
21. Seeger T.F., Bartlett B., Coskran T.M., Culp J.S., James L.C., Krull D.L., Lanfear J., Ryan A.M., Schmidt C.J., Strick C.A., Varghese A.H., Williams R.D., Wylie P.G., Menniti F.S. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003, 985:113-126.
22. Siuciak J.A., Chapin D.S., Harms J.F., Lebel L.A., McCarthy S.A., Chambers L., Shrikhande A., Wong S., Menniti F.S., Schmidt C.J. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006, 51:386-396.
23. Spiwoks-Becker I., Wolloscheck T., Rickes O., Kelleher D.K., Rohleder N., Weyer V., Spessert R. Phosphodiesterase 10A in the rat pineal gland: localization, daily and seasonal regulation of expression and influence on signal transduction. Neuroendocrinology 2011, 94:113-123.
24. 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole. J. Nucl. Med. 2006, 47:345-353.
25. Tu Z., Xu J., Jones L.A., Li S., Mach R.H. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl. Med. Biol. 2010, 37:509-516.
26. 11C]MP-10 as a PET probe for imaging PDE10A in rodent and nonhuman primate brain. Bioorg. Med. Chem. 2011, 19(5):1666-1673.
27. Verhoest P.R., Chapin D.S., Corman M., Fonseca K., Harms J.F., Hou X., Marr E.S., Menniti S.F., Nelson F., O'Connor R., Pandit J., Proulx-LaFrance C., Schmidt A.W., Schmidt C.J., Suiciak J.A., Liras S. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J. Med. Chem. 2009, 52:5188-5196.
28. Walker M.A. Discovery of PDE10A inhibitor, PF-2545920. Drug Discov. Today 2010, 15:79.
29. Wong D.F., Tauscher J., Gründer G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009, 3:187-203.
30. 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J. Nucl. Med. 2006, 47:520-527.